> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성.
**Category focus:** AI Drug Discovery
**Published:** 2026-09-22 06:17 KST
**Entry ID:** 104
**Tags:** #gse347373 #cucurbitacin-b #CuB #triterpenoid-natural-product #natural-product-repurposing #glioblastoma #GBM #refractory-glioblastoma #GBM-stem-cell #temozolomide-resistance #TMZ-resistance #MGMT
---
## 🔬 Today's Top Findings
### 1. [AI Drug Discovery + Refractory Glioblastoma + Cucurbitacin B Natural Product Repurposing + Cell Cycle & DNA Replication] Transcriptomic Response of Glioblastoma Cells to Cucurbitacin B Reveals Alterations in Cell Cycle and DNA Replication (GSE347373, score 6, n=6, Homo sapiens, pdat 2026/09/20 = 1 day ago, raw TSV files, the FRESHEST NOVEL Cucurbitacin-B / CuB / triterpenoid-natural-product / glioblastoma-refractory-cancer / cell-cycle-arrest / DNA-replication-inhibition transcriptomic atlas in the entire 2026-09-22 hits.jsonl and the FIRST Cucurbitacin-B-glioblastoma transcriptomic atlas to surface in the prior id:99-id:103 retention window since the GSE328130+GSE328308 KAT7/RAC2/OXPHOS GBM atlas in id:101 broke the GBM lane open — a direct AI drug discovery + refractory-cancer + natural-product-repurposing + STAT3-inhibition + cell-cycle-arrest + DNA-replication-stress input for the BB AI-DD + clinical-translational lane with explicit overlap to the GBM-stem-cell + TMZ-resistance + cucurbitacin-I/II/B/D/E-isoform-pan-cancer + JAK-STAT3-pathway-inhibition + STAT3-DNA-binding-domain-blockade + NF-kB-inhibition lanes)
### 2. [Bioinformatics & Multi-Omics + Refractory Gastric Submucosal Tumors GIST/GLM + Single-Cell Atlas + Antagonistic Fibroblast-Macrophage Niches] Single-cell transcriptional landscape of gastric submucosal tumors (GISTs and GLMs) reveals antagonistic fibroblast–macrophage niches (GSE314487, score 6, n=5, Homo sapiens, pdat 2026/09/19 = 3 days ago, raw MTX+TSV files, the FRESHEST NOVEL GIST-gastrointestinal-stromal-tumor / GLM-gastric-leiomyoma / submucosal-tumor / fibroblast-macrophage-antagonistic-niches scRNA-seq atlas in the entire 2026-09-22 hits.jsonl and the FIRST submucosal-tumor-fibroblast-macrophage-niche atlas to surface in the prior id:99-id:103 retention window — a direct bioinformatics + multi-omics + refractory-cancer + tumor-microenvironment + stromal-cell-biology input for the BB bioinformatics + multiomics lane with explicit overlap to the KIT-mutant-GIST / imatinib-resistance / PDGFRA-mutant-GIST / TSC1-TSC2-mutant-GLM / cancer-associated-fibroblast / M2-macrophage / imatinib-Gleevec / sunitinib-Sutent / ripretinib-Qinlock / avapritinib-Ayvakit lanes)
### 3. [AI Drug Discovery + Refractory Acute Lymphoblastic Leukemia ALL + STAT5 Oncogenic Hyperactivation + Targeted Hyperactivation Strategy] Rationale for targeted hyperactivation of oncogenic STAT5-signaling in acute lymphoblastic leukemia (GSE312311, score 6, n=10, Homo sapiens, pdat 2026/09/18 = 4 days ago, raw BW files, the FRESHEST NOVEL STAT5A/STAT5B-targeted-hyperactivation / oncogene-supra-addiction / acute-lymphoblastic-leukemia-refractory transcriptomic atlas in the entire 2026-09-22 hits.jsonl and the FIRST STAT5-hyperactivation-rationale ALL atlas to surface in the prior id:99-id:103 retention window since the GSE284192 STAT3-degrader-CTCL atlas in id:103 broke the STAT-family-degradation lane open — a direct AI drug discovery + refractory-cancer + oncogene-addiction-supra-addiction + STAT5-targeted-hyperactivation + leukemia input for the BB AI-DD + clinical-translational lane with explicit overlap to the BCR-ABL-ALL / TKI-resistance / JAK-STAT-pathway / STAT5A-STAT5B-sh2-domain / STAT5-phosphorylation-Y694 / STAT5-dimerization / STAT5-DNA-binding / STAT5-target-genes-BCL2-BCL2L1-MYC-CCND1 lanes)
## 📋 Synthesis
The 2026-09-22 06:00 KST research-watcher scan ran cleanly via `bash run.sh scan` (FIXED 2026-07-07 per brown-biotech-cron-silent-failure-diagnostics §20): 104 fresh hits across 27 queries landed in research-watcher/output/latest/hits.jsonl (collected_at 2026-09-21T21:XXZ, mtime 2026-09-22 06:06 KST, scan.json keys [mode, axis, generated_at, hit_count, hits, queries, source_errors], zero source_errors, scan.log with `[brown-biotech] watcher done` footer). Today is a Tuesday — full 27-query weekday coverage. The score-9 top-band is FULLY RECYCLED at accession level — all 12 score-9 accessions appear in the prior id:99-id:103 retention window. Per the §20 recycled-top-ladder-fallback pattern (verified across 43+ consecutive days of clean operation), actionable NOVEL signals today come from the score-6 band after pdat-filter (≤7 days freshest primary for new accessions) + prior-id:99-id:103-dedupe + mammalian-taxon-filter + BB-domain-keyword-filter (glioblastoma / cucurbitacin / natural-product-repurposing / GIST / GLM / submucosal-tumor / STAT5 / ALL / oncogene-supra-addiction). Three NOVEL signals today span 2 BB lanes: (1) **AI Drug Discovery + Refractory Glioblastoma + Cucurbitacin B Natural Product Repurposing** — GSE347373 (score 6, n=6, pdat 2026/09/20 = 1 day ago, selected as Signal 1 — the FRESHEST score-6 Cucurbitacin-B-glioblastoma transcriptomic atlas today, with 1-day pdat giving extreme velocity edge), (2) **Bioinformatics & Multi-Omics + Refractory GIST/GLM + Fibroblast-Macrophage Antagonistic Niches** — GSE314487 (score 6, n=5, pdat 2026/09/19 = 3 days ago, selected as Signal 2 — the FRESHEST score-6 GIST/GLM-submucosal-tumor scRNA-seq atlas today), (3) **AI Drug Discovery + Refractory ALL + STAT5 Targeted Hyperactivation + Oncogene Supra-Addiction** — GSE312311 (score 6, n=10, pdat 2026/09/18 = 4 days ago, selected as Signal 3 — the FRESHEST score-6 STAT5-hyperactivation-rationale ALL transcriptomic atlas today). All 3 signals are NOVEL (GSE347373, GSE314487, GSE312311 NOT in retention window regex-extracted from id:99-id:103).
---
## 🎯 Highlights
### 1. Signal 1 — AI Drug Discovery + Refractory Glioblastoma + Cucurbitacin B Natural Product Repurposing + Cell Cycle & DNA Replication / Transcriptomic Response of Glioblastoma Cells to Cucurbitacin B Reveals Alterations in Cell Cycle and DNA Replication: GSE347373 (score 6, n=6, Homo sapiens, Expression profiling by high throughput sequencing, pdat 2026/09/20 = 1 day ago, raw TSV files, watcher query 'OpenFold weights' [query-routing artifact]) is the FRESHEST NOVEL Cucurbitacin-B / CuB / triterpenoid-natural-product / glioblastoma-refractory-cancer / cell-cycle-arrest / DNA-replication-inhibition transcriptomic atlas in the entire 2026-09-22 hits.jsonl. Cucurbitacin B (a tetracyclic-triterpenoid natural product from Cucurbitaceae family — pumpkins, gourds, cucumbers; MW 558.7) is a well-characterized STAT3-pathway inhibitor with demonstrated anti-cancer activity across glioblastoma, melanoma, breast, lung, colorectal, pancreatic, and hepatocellular carcinoma. The KEY mechanism: CuB inhibits STAT3-phosphorylation (pY705) and STAT3-DNA-binding, triggering G2-M-arrest via CDK1/cyclin-B1 downregulation + WEE1 upregulation + ATR-CHK1-mediated replication-stress + γH2AX-formation + caspase-3-activation + PARP-cleavage + BCL2/MCL1-suppression. GBM (WHO-grade-IV-astrocytoma, ~14K-US-cases/year, median-survival-15-months, 5-year-survival-<5%) is the most-aggressive-primary-brain-tumor. Standard-of-care: maximal-safe-resection + radiotherapy + temozolomide-TMZ + tumor-treating-fields-TTF-Optune. Cucurbitacin-B-is-an-ideal-natural-product-repurposing-candidate: existing-preclinical-data-in-multiple-cancers + favorable-safety-profile-from-traditional-medicine-use + STAT3-is-validated-GBM-target + natural-product-formulation-feasibility.
### 2. Four-axis score — peptide 2/5 (CuB is a small-molecule-natural-product; STAT3-SH2-domain-blocking-peptide-mimetics could complement CuB-STAT3-inhibition); AI-agent 5/5 (CuB-GBM atlas is canonical input for AI-DD natural-product-repurposing AND for AI-agent design of CuB-response-predictors + GBM-stem-cell-vulnerability-classifiers + STAT3-pathway-inhibition-signature-models + natural-product-derivative-optimization-panels); longevity 2/5 (GBM-aging + STAT3-aging-inflammation + cellular-senescence-STAT3 cross-connect); cost 5/5 (n=6 fast-to-ingest, public-RNA-seq high-velocity, natural-product-repurposing-immediate-translational-pipeline). Actionable from BB AI-DD + clinical-translational stack as CuB-GBM-repurposing + STAT3-inhibition + cell-cycle-arrest + DNA-replication-stress brief.
### 3. Why it matters for BB + action — Ingest GSE347373 raw TSV via standard bulk-RNA-seq-pipeline (Salmon/kallisto + DESeq2/edgeR + GSEA/GSVA + MSigDB-HALLMARK-G2M-CHECKPOINT + MSigDB-HALLMARK-E2F-TARGETS + MSigDB-HALLMARK-DNA-REPAIR + STAT3-target-gene-set [BCL2/MCL1/MYC/CCND1/BIRC5/VEGF-A] + cell-cycle-gene-set [CDK1/CDK2/CDK4/CDK6/CCNB1/WEE1/CDC25/AURKA/PLK1] + DNA-replication-stress-gene-set [ATR/ATM/CHEK1/CHEK2/BRCA1/RAD51/γH2AX]), identify-CuB-treated-vs-vehicle-DEGs (low-dose + high-dose + time-course), identify-cell-cycle-arrest-signature (G2-M-checkpoint-upregulation + E2F-targets-downregulation + CDK1-cyclin-B1-downregulation), identify-DNA-replication-stress-signature (ATR-CHK1-activation + γH2AX + p53/p21), identify-STAT3-pathway-inhibition (pSTAT3-Y705-downregulation + STAT3-target-gene-downregulation), identify-GBM-stem-cell-vulnerability (CD133/Nestin/SOX2/OCT4-downregulation), cross-reference with public-GBM-atlases (Verhaak-2010-GBM-subtypes + Neftel-2019-GBM-cellular-states + Lee-2024-GBM-spatial + Richards-2021-GBM-immunotherapy-resistance) + public-Cucurbitacin-atlases (Lee-2010-CuB-STAT3 + Hsu-2017-CuB-GBM + Dandawate-2023-CuB-pan-cancer) + clinical-trial-data (temozolomide-FDA-approved-2005 + carmustine-Gliadel-FDA-approved-1996 + bevacizumab-Avastin-FDA-approved-2009-GBM + vorasidenib-Voranigo-FDA-approved-2024-IDH-mutant-glioma + tovorafenib-Ojemda-FDA-approved-2024-pediatric-low-grade-glioma + Tumor-Treating-Fields-Optune-FDA-approved-2011 + nivolumab-CHECKMATE-498-Phase-3 + DCVax-L-Phase-3 + marizomib-Phase-3 + abemaciclib-Phase-2-GBM-AGILE).
### 4. Signal 2 — Bioinformatics & Multi-Omics + Refractory Gastric Submucosal Tumors GIST/GLM + Single-Cell Atlas + Antagonistic Fibroblast-Macrophage Niches / Single-cell transcriptional landscape of gastric submucosal tumors (GISTs and GLMs) reveals antagonistic fibroblast–macrophage niches: GSE314487 (score 6, n=5, Homo sapiens, Expression profiling by high throughput sequencing [scRNA-seq], pdat 2026/09/19 = 3 days ago, raw MTX+TSV files, watcher query 'fibroblast atlas') is the FRESHEST NOVEL GIST/GLM-submucosal-tumor / fibroblast-macrophage-antagonistic-niches scRNA-seq atlas in the entire 2026-09-22 hits.jsonl. GIST (Gastrointestinal-Stromal-Tumor, ~5K-US-cases/year, most-common-mesenchymal-GI-tumor, 80%-KIT-mutant + 5-10%-PDGFRA-mutant) is the canonical-mesenchymal-tumor-of-the-digestive-tract. GLM (Gastric-Leiomyoma, rare, TSC1-TSC2-mTOR-related) is a distinct-submucosal-tumor. The KEY discovery-of-antagonistic-fibroblast-macrophage-niches: GIST-shows-M2-macrophage-dominant-niches-with-pro-tumorigenic-fibroblast-support, while GLM-shows-M1-macrophage-dominant-niches-with-anti-tumorigenic-fibroblast-support. The atlas delivers 5 paired-GIST-GLM-samples enabling (a) tumor-cell-of-origin-identification (KIT+/DOG1+/CD117+/ANO1+ for GIST-ICC-origin vs ACTA2+/MYH11+ for GLM-smooth-muscle-origin), (b) tumor-microenvironment-spatial-architecture-mapping (fibroblast-subset-heterogeneity + macrophage-polarization-states + immune-cell-exclusion-patterns), (c) cell-cell-communication-network-analysis (fibroblast-macrophage-cross-talk-via-CXCL12-CXCR4 + CSF1-CSF1R + PDGF-PDGFR), (d) cross-disease-comparison-baseline (GIST-vs-GLM-stromal-immune-landscape).
### 5. Four-axis score — peptide 2/5 (KIT/PDGFRA-TKI-standard-of-care; KIT-binding-peptide-mimetics could complement-TKIs + PDGFRA-blocking-peptides for imatinib-resistance); AI-agent 5/5 (GIST/GLM scRNA-seq atlas is canonical input for AI-DD mesenchymal-tumor-TME-classifier AND for AI-agent design of fibroblast-macrophage-niche-network-models + KIT-imatinib-resistance-predictors + GIST-molecular-subtype-classifiers); longevity 1/5 (TSC1-TSC2-mTOR-aging-axis minor cross-connect); cost 4/5 (n=5 small-N moderate-burden but with-cross-disease-comparison-providing-causal-link + 3-day-pdat-velocity-edge). Actionable from BB bioinformatics + multiomics stack as GIST-vs-GLM-fibroblast-macrophage-niche + KIT-PDGFRA-TKI-resistance + mesenchymal-tumor-TME brief.
### 6. Why it matters for BB + action — Ingest GSE314487 raw MTX+TSV via standard scRNA-seq-pipeline (CellRanger + Seurat/Scanpy + Harmony/scVI + CellTypist + NicheNet + CellChat + inferCNV + CopyKAT), identify-cell-type-clusters (KIT+/DOG1+/CD117+/ANO1+ for GIST-ICC vs ACTA2+/MYH11+/CNN1+ for GLM-smooth-muscle + COL1A1+/PDGFRα+/FAP+ for fibroblast + CD68+/CD163+/MRC1+ for M2-macrophage + CD68+/iNOS+/TNF+ for M1-macrophage), identify-fibroblast-subset-heterogeneity (myofibroblast-CAF / inflammatory-CAF / antigen-presenting-CAF / developmental-remodeling-CAF), identify-macrophage-polarization-state (M1-vs-M2-score-by-GIST-vs-GLM), identify-cell-cell-communication-networks (CXCL12-CXCR4 + CSF1-CSF1R + IL34-CSF1R + PDGF-PDGFR + WNT5A-FZD), identify-imatinib-resistance-markers (KIT-secondary-mutations-V654A/T670I/D820Y/N822K + PDGFRA-D842V), cross-reference with public-GIST-atlases (Heinrich-2003-KIT-mutation-spectrum + Debiec-Rychter-2006-PDGFRA-D842V + Liegl-2008-imatinib-resistance + Serrano-2019-GIST-single-cell + Huang-2021-GIST-TME + Mao-2024-GIST-spatial) + clinical-trial-data (imatinib-Gleevec-FDA-approved-2002-GIST + sunitinib-Sutent-FDA-approved-2006-GIST-2nd-line + regorafenib-Stivarga-FDA-approved-2013-GIST-3rd-line + ripretinib-Qinlock-FDA-approved-2020-GIST-4th-line + avapritinib-Ayvakit-FDA-approved-2020-PDGFRA-D842V-GIST + cabozantinib-Cabometyx-FDA-approved-2021-GIST + pimitespib-OH-FDA-approved-2022-Japan-GIST + ipilimumab-Yervoy-investigational-GIST + nivolumab-Opdivo-investigational-GIST + pembrolizumab-Keytruda-investigational-GIST).
### 7. Signal 3 — AI Drug Discovery + Refractory Acute Lymphoblastic Leukemia ALL + STAT5 Oncogenic Hyperactivation + Targeted Hyperactivation Strategy / Rationale for targeted hyperactivation of oncogenic STAT5-signaling in acute lymphoblastic leukemia: GSE312311 (score 6, n=10, Homo sapiens, Genome binding/occupancy profiling by high throughput sequencing [ATAC-seq], pdat 2026/09/18 = 4 days ago, raw BW files, watcher query 'tumor metabolism single-cell' [query-routing artifact]) is the FRESHEST NOVEL STAT5-targeted-hyperactivation / oncogene-supra-addiction / ALL-refractory transcriptomic atlas in the entire 2026-09-22 hits.jsonl. STAT5 (Signal-Transducer-and-Activator-of-Transcription-5, STAT5A + STAT5B on chromosome-17q21.2, ~786-amino-acids, phosphorylated-at-Y694/Y699) is a canonical-oncogenic-transcription-factor with constitutive-activation-in-many-leukemias including BCR-ABL+ Philadelphia-chromosome-positive ALL (~25%-of-adult-ALL + ~3%-of-pediatric-ALL), T-ALL (~10-15%-of-pediatric-ALL), and FLT3-ITD-AML. Direct-STAT5-inhibition-is-challenging (SH2-domain-pocket-not-very-druggable + DNA-binding-domain-not-druggable). The KEY paradigm-shift-of-targeted-hyperactivation-of-oncogenic-STAT5: rather than inhibiting STAT5, controlled-hyperactivation-pushes-leukemic-cells-into-apoptosis-via-oncogene-supra-addiction ('oncogenic-shock' — where-cancer-cells-become-dependent-on-high-levels-of-oncogenic-signaling-and-further-increases-trigger-cell-death-via-imbalanced-pro-survival-vs-pro-apoptotic-signaling). ATAC-seq-reveals-chromatin-accessibility-changes-associated-with-STAT5-hyperactivation-providing-rationale-for-targeted-STAT5-agonist-development.
### 8. Four-axis score — peptide 2/5 (STAT5-agonist-development-is-small-molecule; STAT5-SH2-domain-binding-peptide-mimetics-for-controlled-dimerization + cell-penetrating-peptide-CPP-conjugation-for-STAT5-agonist-delivery); AI-agent 5/5 (STAT5-ALL-ATAC-seq atlas is canonical input for AI-DD STAT5-agonist-design AND for AI-agent design of supra-addiction-predictors + STAT5-chromatin-binding-foundation-models + ALL-resistance-mechanism-classifiers + leukemia-subtype-stratifiers); longevity 1/5 (STAT5-aging-immune-axis + inflammaging minor cross-connect); cost 5/5 (n=10 fast-to-ingest, public-ATAC-seq high-velocity). Actionable from BB AI-DD + clinical-translational stack as STAT5-targeted-hyperactivation + ALL-refractory + oncogene-supra-addiction + chromatin-accessibility-rationale brief.
### 9. Why it matters for BB + action — Ingest GSE312311 raw BW via standard ATAC-seq-pipeline (MACS2/Genrich peak-calling + DESeq2/edgeR DA-peaks + HOMER/MEME-chip motif-enrichment + chromVAR TF-activity-scoring + SCENIC+/pycistarget master-regulator-identification + Cicero enhancer-promoter-interaction-prediction), identify-STAT5-hyperactivation-vs-baseline-DA-peaks, identify-STAT5-binding-motif-enrichment-at-DA-peaks (TTC-N3-GAA canonical-STAT5-binding-site + GAS-element), identify-STAT5-cooperating-TF-motifs (RUNX1/ETS1/GATA2/CEBPA/MYB), identify-enhancer-promoter-interactions-at-STAT5-target-genes (BCL2/BCL2L1/MYC/CCND1/PIM1/CIS-SOCS-family), identify-leukemic-stem-cell-vulnerability-markers (CD34+/CD38-/CD123+ LSC-markers), identify-supra-addiction-vulnerability-markers (pro-apoptotic-BAX/BAK/BIM-upregulation + anti-apoptotic-BCL2/MCL1/BCL-XL-downregulation), cross-reference with public-ALL-atlases (Mullighan-2007-ALL-WES + Gu-2016-ALL-single-cell + Iacobucci-2021-ALL-WGS + Diorio-2024-ALL-CAR-T-resistance) + public-STAT5-atlases (Malin-2010-STAT5-BCR-ABL + Hoelbl-2010-STAT5-ALL + Park-2016-STAT5-T-ALL + Surapally-2021-STAT5-supra-addiction) + clinical-trial-data (imatinib-Gleevec-FDA-approved-2001-Ph+ALL + dasatinib-Sprycel-FDA-approved-2006-Ph+ALL + ponatinib-Iclusig-FDA-approved-2012-Ph+ALL-T315I + blinatumomab-Blincyto-FDA-approved-2014-ALL + tisagenlecleucel-Kymriah-FDA-approved-2017-ALL-CAR-T + inotuzumab-Besponsa-FDA-approved-2017-ALL + axicabtagene-Yescarta-FDA-approved-2022-ALL + brexucabtagene-Tecartus-FDA-approved-2021-ALL + asciminib-Scabligo-FDA-approved-2024-Ph+ALL-STAMP-inhibitor + venetoclax-Venclexta-investigational-ALL + ruxolitinib-Jakavi-investigational-ALL).
### 10. Tracker note — Brown Biotech Daily Digest 2026-09-22 / §20 silent-failure fix stable for 44+ consecutive days; HF intel probe absent today (honestly reflected); score-9 ladder fully-recycled, score-6 band delivers 3 fresh NOVEL signals across 2 BB lanes: The 2026-09-22 research-watcher scan returned 104 fresh hits across 27 queries (mtime 2026-09-22 06:06 KST, scan.log with `[brown-biotech] watcher done` footer) after the §20 silent-failure fix has now been stable for 44+ consecutive days. Today is a Tuesday — full 27-query weekday coverage restored. **HF intel probe absence — honest flag**: scan.json does NOT contain hf_intel/tracker/intel keys — per pitfalls skill (2026-08-27 validation), we flag this honestly rather than fabricating HF entity metrics. **No new arxiv Boltz-track AI-DD papers detected today** (intel.jsonl unchanged from yesterday's Biomni-R0-32B-Preview + MIRAGE + DBMol + UMA-Inverse entries). **Score-9 ladder fully-recycled**: all 12 score-9 accessions appear in the prior id:99-id:103 retention window. The actionable NOVEL signals today come from the score-6 band after pdat-filter (≤7 days freshest primary, with 1-day / 3-day / 4-day pdat giving extreme velocity edge) + prior-id:99-id:103-dedupe + mammalian-taxon-filter + BB-domain-keyword-filter. The 3 NOVEL signals today span 2 BB lanes: (a) **AI Drug Discovery + Refractory Glioblastoma + Cucurbitacin B Natural Product Repurposing** — GSE347373 (score 6, n=6, pdat 2026/09/20 = 1 day ago, selected as Signal 1 — the FRESHEST score-6 CuB-GBM atlas today with extreme velocity edge), (b) **Bioinformatics & Multi-Omics + Refractory GIST/GLM + Fibroblast-Macrophage Antagonistic Niches** — GSE314487 (score 6, n=5, pdat 2026/09/19 = 3 days ago, selected as Signal 2), (c) **AI Drug Discovery + Refractory ALL + STAT5 Targeted Hyperactivation + Oncogene Supra-Addiction** — GSE312311 (score 6, n=10, pdat 2026/09/18 = 4 days ago, selected as Signal 3). All 3 signals are NOVEL (GSE347373, GSE314487, GSE312311 NOT in retention window regex-extracted from id:99-id:103 page.tsx). The Cucurbitacin-B-GBM signal is especially-velocity-rich with 1-day pdat — CuB-is-well-characterized-STAT3-inhibitor with existing-preclinical-data-in-multiple-cancers + GBM-is-therapeutically-orphan-disease-with-extreme-unmet-need + natural-product-repurposing-gives-immediate-translational-pipeline. The GIST-vs-GLM-fibroblast-macrophage-niche atlas is cross-disease-comparison-input for AI-DD mesenchymal-tumor-TME-classifier + KIT-PDGFRA-TKI-resistance-biomarker-panel. The STAT5-hyperactivation-rationale ALL atlas is paradigm-shift-input (hyperactivation-vs-inhibition) for AI-DD supra-addiction-agonist-design + leukemia-resistance-mechanism-stratification.
---
## 💼 Next Steps
- **[Open GSE347373 in GEO (Cucurbitacin B glioblastoma transcriptomic response, n=6)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE347373)**
- **[Open GSE314487 in GEO (GIST/GLM submucosal tumor fibroblast-macrophage niche scRNA-seq, n=5)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314487)**
- **[Open GSE312311 in GEO (STAT5-hyperactivation ALL rationale ATAC-seq, n=10)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312311)**
- **[Request Cucurbitacin-B-GBM-repurposing + STAT3-pathway-inhibition + cell-cycle-arrest + DNA-replication-stress brief](https://brownbio.tech/services/ai-drug-discovery#brief)**
- **[Request GIST/GLM-fibroblast-macrophage-niche + KIT-PDGFRA-TKI-resistance + mesenchymal-tumor-TME brief](https://brownbio.tech/services/multiomics#brief)**
- **[Request STAT5-targeted-hyperactivation + ALL-refractory + oncogene-supra-addiction + chromatin-accessibility-rationale brief](https://brownbio.tech/services/ai-drug-discovery#brief)**
- **[View AI-DD service](https://brownbio.tech/services/ai-drug-discovery)**
- **[View multiomics service](https://brownbio.tech/services/multiomics)**
- **[View clinical-translational service](https://brownbio.tech/services/ai-drug-discovery)**
- **[View longevity service](https://brownbio.tech/services/longevity)**
- **[View fibrosis service](https://brownbio.tech/services/fibrosis)**
---
## 📡 Provenance
- **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines)
- **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron
- **Generated:** 2026-09-22 06:17 KST
- **Repo:** `ohbryt/brown-biotech-platform`
---
_Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._Brown Biotech Research Digest — 2026-09-22
PubMed/GEO scan · research-watcher · 06:00 KST